How to Reconstitute IGF-1 DES: Step-by-Step Research Lab Protocol
The content, articles and product information provided on this website are strictly educational and informational. They are intended to be used for in vitro research only. “In vitro” is a Latin phrase, “in glass,” that refers to research that is conducted outside of a living organism. Note, these products are not pharmaceuticals or medicines and have not been approved by the FDA for the diagnosis, treatment or prevention of any illnesses or disorders. These products are legally prohibited from human or animal consumption.
How to Reconstitute IGF-1 DES: Step-by-Step Research Lab Protocol
IGF-1 DES (Des(1-3)-IGF-1, MW ~7368 Da) is a truncated IGF-1 analogue lacking the first three N-terminal amino acids (Gly-Pro-Glu) of native IGF-1. This truncation substantially reduces IGFBP-3 binding affinity while maintaining full IGF-1R binding capacity, resulting in significantly increased potency at IGF-1R in IGFBP-containing cell culture conditions. It is supplied as a lyophilised powder in a 10mL sterile glass vial containing 1mg of peptide.
Materials Required
- IGF-1 DES 1mg lyophilised vial
- Sterile 0.1% acetic acid for reconstitution
- Sterile PBS + 0.1% BSA for working dilutions
- 0.5mL or 1mL sterile syringe with needle
- Alcohol swabs (70% isopropyl)
- Nitrile gloves
- Permanent marker for labelling
Important Note on Solvent Selection
Like IGF-1 LR3, IGF-1 DES is reconstituted in sterile 0.1% acetic acid rather than BAC water to maintain protein conformation and prevent aggregation at stock concentrations. All working dilutions must be prepared in PBS + 0.1% BSA or serum-free media to neutralise pH before cell contact. Never add the acetic acid stock directly to cell culture wells without intermediate dilution.
Step-by-Step Reconstitution Protocol
Step 1 — Prepare workspace. Clean surface with 70% isopropyl alcohol. Allow to dry. Wear nitrile gloves.
Step 2 — Swab vial stopper. Wipe rubber stopper with a fresh alcohol swab. Air dry 10 seconds.
Step 3 — Draw 0.5mL of sterile 0.1% acetic acid. Using a sterile syringe, draw 0.5mL of 0.1% acetic acid to yield a 2mg/mL stock.
Step 4 — Inject slowly along the vial wall. Direct the acetic acid solution slowly down the inner glass wall over 15–20 seconds. IGF-1 DES is a protein-class molecule — avoid vigorous injection that could cause denaturation.
Step 5 — Dissolve by gentle swirling. Gently swirl for 30–60 seconds. The solution should be clear and colourless. Do not shake or vortex.
Step 6 — Label. Record date, concentration, solvent, and initials on the vial.
Resulting Concentration
Adding 0.5mL sterile 0.1% acetic acid to a 1mg IGF-1 DES vial yields a stock concentration of 2mg/mL (2000mcg/mL). For IGF-1R activation studies, dilute at least 1:100 into PBS + 0.1% BSA before further serial dilution to working concentrations of 1ng/mL–1mcg/mL for cell model assay applications.
Concentration Reference Table
| Acetic Acid Volume Added | Resulting Concentration |
|---|---|
| 0.5mL | 2.0mg/mL (2000mcg/mL) |
| 1.0mL | 1.0mg/mL (1000mcg/mL) |
Storage Conditions and Stability
Store lyophilised IGF-1 DES at −20°C or −80°C prior to reconstitution. Once reconstituted in 0.1% acetic acid, store at 2–8°C for up to 14 days. Add 0.1% BSA as a carrier protein to improve stability and reduce non-specific adsorption to plastic surfaces. Prepare single-use aliquots in BSA/PBS for −80°C long-term storage. Avoid repeated freeze-thaw cycles.
Troubleshooting Common Reconstitution Issues
Powder not dissolving: If any powder adheres to the glass wall, gently tilt and swirl the vial to bring it into contact with the solvent. Do not heat the vial. If dissolution remains incomplete after 60 seconds of gentle swirling, inspect the vial for signs of moisture ingress or a previously compromised seal.
Cloudy solution: A correctly reconstituted solution should be clear and colourless. Cloudiness may indicate peptide aggregation, microbial contamination, or particulate introduction. Discard the vial if cloudiness persists after gentle swirling and re-inspection.
Foaming: If foam forms, allow it to settle naturally without shaking. Foaming typically results from injecting the solvent too quickly or directly onto the powder — direct the stream along the glass wall and reduce injection speed on subsequent attempts.
Loss of material on vial walls: Swirl the vial so the reconstituted solution contacts all inner wall surfaces before drawing. For maximum peptide recovery, invert the vial and draw from the stopper end after complete dissolution.
Research Application Notes
IGF-1 DES demonstrates approximately 10-fold higher potency than native IGF-1 at IGF-1R in serum-containing cell culture conditions due to reduced IGFBP-3 sequestration. This potency advantage makes it useful for studies where very low nanomolar IGF-1R activation is required. In comparative studies with IGF-1 LR3, IGF-1 DES provides a structurally distinct IGFBP-independent IGF-1R agonist reference point. Always include a 0.1% BSA/PBS vehicle control to account for carrier protein effects on baseline cell signalling. IGF-1 DES 1mg vials are available from Pinnacle Peptides, verified at ≥99% purity by HPLC and mass spectrometry.
All content is intended for in vitro laboratory research purposes only. Not for human or animal consumption. Not intended to diagnose, treat, cure, or prevent any condition.
